Lucinda Warren
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Lucinda Warren
Lucinda Warren is recorded as CEO and CFO at Cue Biopharma, Inc. (CUE). Cue Biopharma, Inc. reported in an 8-K filed May 1, 2026 that Lucinda Warren resigned as Interim President and Chief Executive Officer, effective April 30, 2026. Cue Biopharma, Inc. reported in an 8-K filed March 27, 2026 that Lucinda Warren was appointed Interim President and Chief Executive Officer, effective March 27, 2026. Cue Biopharma, Inc. reported in an 8-K filed February 12, 2026 that Lucinda Warren was appointed Chief Financial and Business Officer, effective February 9, 2026. The proxy statement of Cue Biopharma, Inc. reports total compensation of $801,223 for Lucinda Warren in fiscal 2025, including a base salary of $469,952.
“Dr. Lin will succeed Lucinda Warren whose resignation as Interim President and Chief Executive Officer was effective as of April 30, 2026, and whose resignation from all other roles and employment with the Company takes effect as of the date set forth in the Warren Separation Agreement (as defined below) (the “Separation Date”), with the Separation Date anticipated to be on or around May 4, 2026.”
“On March 26, 2026, the Board of Directors (the "Board") of Cue Biopharma, Inc. (the "Company") appointed Lucinda Warren, the Chief Financial and Business Officer of the Company, as Interim President and Chief Executive Officer, effective as of March 27, 2026 (the "Effective Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-03-27–present
-
Current
2026-02-09–present
-
Cue Biopharma, Inc. (CUE)
Proxy statement
CurrentStart not stated–present
-
2026-03-27–2026-04-30
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Cue Biopharma, Inc.
Other people whose current roles at this company are on record from its filings.
- Daniel R. Passeri CEO, Board Member
- Dr. Shao-Lee Lin CEO, Board Member
- Usman Azam CEO, Board Member
- James Ahlers CFO
- Kerri Millar CFO
- Colin G. Sandercock General Counsel
- Sumita Ray General Counsel
- Michael Meluzio Chief Accounting Officer
- Daniel Camardo Board Member
- Jill Broadfoot Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cue Biopharma, Inc. (CUE) | Chief Financial and Business Officer | $469,952 | $801,223 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.